First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: A multicenter experience

Neurosurgical Review

Volumn 33, Issue 4, 2010, Pages 441-449

  Bock, Hans Christoph ^a   Puchner, Maximilian Josef Anton ^b   Lohmann, Frauke ^b   Schütze, Michael ^c   Koll, Simone ^d   Ketter, Ralf ^e   Buchalla, Ruediger ^f   Rainov, Nikolai ^g   Kantelhardt, Sven R ^a   Rohde, Veit ^a   Giese, Alf ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Department of Neurosurgery   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d KLINIKUM FULDA   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f Ev Luth Diakonissenanstalt Flensburg ^*  (Germany)

^g KLINIKUM AUGSBURG   (Germany)

Author keywords

BCNU; Carmustine; Gliadel; Glioma; Local chemotherapy; Radiochemotherapy; Temozolomide

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CORTICOSTEROID DERIVATIVE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TEMOZOLOMIDE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN ABSCESS; BRAIN EDEMA; BRAIN INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; LEUKOPENIA; LIQUORRHEA; LUNG EMBOLISM; MALE; MENINGITIS; MENTAL DEFICIENCY; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROSURGERY; OVERALL SURVIVAL; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; SEIZURE; THROMBOCYTOPENIA; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG IMPLANTS; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957606545     PISSN: 03445607     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10143-010-0280-7     Document Type: Article

References (27)

1. Asher A (2007) Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma. Abstract presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington, DC 2007
2. H Brem S Piantadosi PC Burger M Walker R Selker NA Vick K Black M Sisti S Brem G Mohr, et al. 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet 345 1008 1012 1:STN:280:DyaK2M3ktVansw%3D%3D 10.1016/S0140-6736(95)90755-6 7723496
3. Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003 ( http://ctep.cancer.gov ). Publish Date: August 9
4. BJ Darakchiev RE Albright JC Breneman RE Warnick 2008 Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme J Neurosurg 108 236 242 10.3171/JNS/2008/108/ 2/0236 18240917 (Pubitemid 351213285)
5. LK Fung MG Ewend A Sills EP Sipos R Thompson M Watts OM Colvin H Brem WM Saltzman 1998 Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain Cancer Res 58 672 684 1:CAS:528:DyaK1cXht1antbY%3D 9485020
6. Giese A, Bock HC, Kantelhardt SR, Rohde V (2010): Risk Management in the Treatment of Malignant Gliomas with BCNU Wafer Implants. Jan 8. doi: 10.1055/s-0029-1242775
7. S Gururangan L Cokgor JN Rich S Edwards ML Affronti JA Quinn JE Herndon 2nd JM Provenzale RE McLendon S Tourt-Uhlig JH Sampson V Stafford-Fox S Zaknoen M Early AH Friedman HS Friedman 2001 Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro Oncol 3 246 250 1:CAS:528:DC%2BD38Xks1Olsrs%3D 11584894
8. Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ et al (2006) Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Journal Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol 24(18S), p 11504
9. R LaRocca S Glisson J Hargis D Petruska W Villanueva D Morassutti, et al. 2006 High-grade glioma treated with surgery; carmustine wafer; postoperative radiation; and procarbazine, lomustine, and vincristine chemotherapy Neurosurg Q 15 3 167 171 10.1097/01.wnq.0000174599.99440.68
10. LaRocca RV, Hodes J, Villanueva WG, Vitaz TW, Morassutti DJ, Doyle MJ, et al (2006) A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion: Abstract presented at the Annual Meeting of the Society of Neuro-oncology, Orlando, FL (Abstract)
11. Lawson DH, Phuphanich S, McKenzie E, Greiner K, Shires K, Olson J (2006) Phase I analysis of systemic interferon alpha utilized with gliadel in adults with recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, Vol 24, No 18S (June 20 Supplement), p 11508
12. SA Limentani A Asher M Heafner JW Kim R Fraser 2005 A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme J Neurooncol 72 241 244 1:CAS:528:DC%2BD28Xltw%3D%3D 10.1007/s11060-004-2339-1 15937647 (Pubitemid 40867407)
13. MJ McGirt KD Than JD Weingart KL Chaichana FJ Attenello A Olivi J Laterra LR Kleinberg SA Grossman H Brem A Quiñones-Hinojosa 2009 Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 3 583 588 1:CAS:528:DC%2BD1MXjvVyns7g%3D 10.3171/2008.5.17557 19046047
14. PC McGovern E Lautenbach PJ Brennan RA Lustig NO Fishman 2003 Risk factors for postcraniotomy surgical site infection after 1, 3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement Clin Infect Dis 36 759 765 1:CAS:528:DC%2BD3sXjtVKqtbc%3D 10.1086/368082 12627360 (Pubitemid 36337980)
15. MGI Pharma (2006) Gliadel® Wafer [prescribing information] MGI PHARMA, Bloomington
16. MGI Pharma (2006) Gliadel® Wafer [summary of product characteristics] MGI PHARMA, West Sussex, UK
17. E Pan SB Mitchell JS Tsai 2008 A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients J Neurooncol 88 353 357 10.1007/s11060-008-9576-7 18389176
18. J Plowman WR Waud AD Koutsoukos LV Rubinstein TD Moore MR Grever 1994 Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1, 3-bis(2-chloroethyl)-1-nitrosourea Cancer Res 54 3793 3799 1:CAS:528:DyaK2cXkvF2htbo%3D 8033099
19. M Sabel A Giese 2008 Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience Curr Med Res Opin 24 11 3239 3257 1:CAS:528:DC%2BD1MXks1Cgtg%3D%3D 10.1185/03007990802508180
20. Sampath P, Weaver CE, Alderson L, Duncan JA, Stopa E, Fountas KN (2005) Consecutive use of brachytherapy (Gliasite) and intratumoral chemotherapy (Gliadel) for recurrent glioblastoma: a phase I/II study with independent clinical review. Poster and abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA, (Abstract)
21. Smith KA, Ashby L, Gonzolas F (2006) Gross total resection (GTR) with Gliadel® Wafer implantation followed by post-operative gamma knife radiosurgery and adjuvant fractionated radiotherapy for newly diagnosed GBM: phase I/II study of safety and efficacy in 30 consecutive patients. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Chicago, IL (Abstract)
22. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
23. RJ Tamargo JI Epstein CS Reinhard M Chasin H Brem 1989 Brain biocompatibility of a biodegradable, controlled-release polymer in rats J Biomed Mater Res 23 253 266 1:CAS:528:DyaL1MXht1Whu7w%3D 10.1002/jbm.820230209 2708412 (Pubitemid 19042070)
24. S Valtonen U Timonen P Toivanen H Kalimo L Kivipelto O Heiskanen G Unsgaard T Kuurne 1997 Interstitial chemotherapy with carmustine-loaded polymers for high grade gliomas: A randomized double-blind study Neurosurg 41 44 49 1:STN:280:DyaK2szmtFCjsg%3D%3D 10.1097/00006123-199707000-00011 (Pubitemid 27282080)
25. M Westphal DC Hilt E Bortey P Delavault R Olivares PC Warnke, et al. 2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 5 79 88 1:CAS:528:DC%2BD3sXjtVKltL4%3D 12672279
26. M Westphal Z Ram V Riddle D Hilt E Bortey 2006 Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 269 275 1:STN:280:DC%2BD28znvFWmtQ%3D%3D 10.1007/s00701-005-0707-z discussion 275
27. Zamorano L, Li Q, Levin K, Barger G (2005) Brachytherapy with I-125 permanent implant combined with sequential Gliadel in the treatment of patients with GBM. Abstract presented at the Annual Meeting of the Congress of Neurological Surgeons, Boston, MA (Abstract)